Search research articles
Contact Us
Filters
Showing results (31-40 of 101) with videos related to
Page
of 11
Sort By:
Immunotherapy
|
June 30, 2021
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
Antonello Veccia, Vincenzo Sforza, Emanuela Vattemi, et al.
Cancers
|
March 11, 2023
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Translational Cancer Research
|
June 17, 2024
Distribution characteristics and prognosis of tumor-infiltrating lymphocytes in the brain metastases of small cell lung cancer: a retrospective cohort study
Hesheng Qian, Jingdan Pang, Chang Wan, et al.
Hospital Pharmacy
|
November 19, 2024
Rapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh
Roberto Tessari, Andrea Ossato, Francesca Realdon, et al.
International Journal of Molecular Sciences
|
April 27, 2024
Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside-Part 1
Giuseppina Gallucci, Fabio Maria Turazza, Alessandro Inno, et al.
Tumori
|
May 13, 2017
Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity
Alessandro Inno, Giulio Metro, Paolo Bironzo, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2015
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians
Filippo Pietrantonio, Armando Orlandi, Alessandro Inno, et al.
Frontiers in Oncology
|
May 25, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Frontiers in Oncology
|
July 14, 2026
Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Pharmacogenomics
|
December 1, 2015
BRAF in metastatic colorectal cancer: the future starts now
Armando Orlandi, Alessandra Calegari, Alessandro Inno, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 101) with videos related to
Sort By:
Page
of 11
Immunotherapy
|
June 30, 2021
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
Antonello Veccia, Vincenzo Sforza, Emanuela Vattemi, et al.
Cancers
|
March 11, 2023
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Translational Cancer Research
|
June 17, 2024
Distribution characteristics and prognosis of tumor-infiltrating lymphocytes in the brain metastases of small cell lung cancer: a retrospective cohort study
Hesheng Qian, Jingdan Pang, Chang Wan, et al.
Hospital Pharmacy
|
November 19, 2024
Rapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh
Roberto Tessari, Andrea Ossato, Francesca Realdon, et al.
International Journal of Molecular Sciences
|
April 27, 2024
Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside-Part 1
Giuseppina Gallucci, Fabio Maria Turazza, Alessandro Inno, et al.
Tumori
|
May 13, 2017
Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity
Alessandro Inno, Giulio Metro, Paolo Bironzo, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2015
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians
Filippo Pietrantonio, Armando Orlandi, Alessandro Inno, et al.
Frontiers in Oncology
|
May 25, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Frontiers in Oncology
|
July 14, 2026
Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, et al.
Pharmacogenomics
|
December 1, 2015
BRAF in metastatic colorectal cancer: the future starts now
Armando Orlandi, Alessandra Calegari, Alessandro Inno, et al.
Page
of 11